All Columns articles
-
OpinionUK budget aims to promote ‘reindustrialisation’
Chancellor affirmed funding for previously introduced support measures, but competitiveness challenges remain
-
OpinionLearning the language of chemistry
Chemical structures embed vast amounts of information that needs translating for machines
-
OpinionUS atrazine cancer lawsuit revives hazard vs risk debate in pesticide regulation
Should firms have to issue cancer warnings in states that use different assessment criteria to national regulators?
-
ArticleA Nobel for chiral catalysts’ helping hand
This year’s laureates didn’t invent asymmetric synthesis, but filled in our understanding of how it works and how we can do it better
-
OpinionIneos temporarily closes UK acetyls plants
Owing to high high gas prices, the plants are uncompetitive, despite their high efficiency
-
OpinionFeeding AI’s appetite for data
Tapping companies’ archives makes for better predictions of how proteins bind drugs, but any data inputs need to be transparent and attributed
-
Opinion‘Molecular glues’ are sticking it to cancer
Compounds that enhance selected protein–protein interactions to interfere with signalling or send proteins to be destroyed are making it possible to influence processes that were previously considered ‘undruggable’
-
OpinionDeadly reminders of the importance of risk assessment
Serious incidents in two university labs highlight the importance of knowing what to do when things go wrong
-
OpinionOur cosmic origins remain plausible, not proven
The evidence is there that the molecular ingredients for life can form in space, but that doesn’t mean that they did
-
OpinionArtificial intelligence or clever artifice?
It’s important to be realistic about what AI can, and can’t, achieve, across the chemistry enterprise
-
OpinionMessy megamergers
Rumoured merger between AstraZeneca and Bristol Myers Squibb has collapsed, and that’s probably a good thing
-
OpinionTrump threatens generic drug tariffs
Plan aims to encourage domestic US supplies, but will it work?
-
OpinionWhere does chemical recycling of plastics go from here?
US and EU plant closures highlight economic difficulties of scaling technology alongside associated policy and infrastructure
-
OpinionTrust is easily broken and hard to rebuild
Thermo Fisher needs to be open and honest about data manipulation to reassure researchers
-
OpinionIs industry getting more or less safe?
US figures suggest an increase in incidents involving serious injuries and fatalities in recent years
-
OpinionShould the EU stop exports of pesticides it has banned?
Agrochemicals including paraquat remain legal elsewhere, prompting questions over regulatory responsibility
-
OpinionWhat kinds of reactions do you do most?
Variety may be the spice of life, but there’s space for the boring but effective
-
OpinionGSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
-
OpinionHow far will EU push for fairer trade with China?
Strengthening rules on pharmaceutical and chemical trade could protect critical industries
-
